<DOC>
	<DOCNO>NCT00525044</DOCNO>
	<brief_summary>The aim trial investigate efficacy tolerance Ambroxol lozenges 20 mg treatment sore throat patient acute viral pharyngitis .</brief_summary>
	<brief_title>Double-blind Trial Investigate Efficacy Tolerance Ambroxol Lozenges 20 mg Sore Throat</brief_title>
	<detailed_description>Male female ambulant patient complain sore throat cause acute viral pharyngitis . Every patient may include trial . A total 250 male female ambulant patient age 18 65 year enrol . Approximately 8 center recruit enrol approximately 30-32 patient . Study Hypothesis : The two-sided test hypothesis , result active treatment group 20 mg Ambroxol placebo group differ regard primary endpoint ( null hypothesis ( H0 ) test alternative ( H1 ) equal . Comparison ( ) : PRIMARY ENDPOINT : Indication pain VRS ( PI ) -verbal rating scale ( pain intensity ) -in first 3 hour ( patient rate his/her pain six-point verbal rating scale ) . SECONDARY ENDPOINT ( S ) : 1 . Patient 's assessment effectiveness tolerance . The patient assess effectiveness tolerance test medicine treat sore throat end first second day treatment , mean verbal rating scale . 2 . Participating doctor assessment tolerance .</detailed_description>
	<mesh_term>Pharyngitis</mesh_term>
	<mesh_term>Ambroxol</mesh_term>
	<criteria>1 . Patients sore throat acute viral pharyngitis . 2 . Female male ambulant patient age 18 65 . 3 . The throat pain intensity rat least severe VRS ( PI ) . 4 . Written Informed Consent give patient . 5 . Compliance patient seem guarantee . 1 . Patients symptoms primarily bacterial pharyngitis bacterial secondary infection ( clinical finding ; inter alia assessment exudate ) . 2 . First indication symptom acute pharyngitis ( e.g. , sore throat ) occur 3 day ago already . 3 . Counting white blood cell blood routine examination exceed 10 ? 109/L . 4 . Patients suffer acute viral bacterial pharyngitis past 4 week . 5 . Bronchomotor disorder concomitant disease relatively large quantity secretion ( danger secretion blockage ) . 6 . Known hypersensitivity Ambroxol auxiliary substance contain tablet . 7 . Previous and/or exist tumour condition . 8 . Pregnancy and/or breastfeed . 9 . Alcohol , and/or drug abuse . 10 . Simultaneous participation another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>